Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
The current price of RGEN.BOATS is $175.20 USD — it has decreased by -1.02% in the past 24 hours. Watch Repligen stock price performance more closely on the chart.
What is Repligen stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Repligen stocks are traded under the ticker RGEN.BOATS.
What is Repligen market cap?▼
Today Repligen has the market capitalization of 11.12B
When is the next Repligen earnings date?▼
Repligen is going to release the next earnings report on February 24, 2027.
What were Repligen earnings last quarter?▼
RGEN.BOATS earnings for the last quarter are 0.53 USD per share, whereas the estimation was 0.46 USD resulting in a +14.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Repligen revenue for the last year?▼
Repligen revenue for the last year amounts to 738.26M USD.
What is Repligen net income for the last year?▼
RGEN.BOATS net income for the last year is 48.89M USD.